RENO, Nev.--(BUSINESS WIRE)--First graph, second sentence of release dated April 26, 2007 should read: Lifeline Biotechnologies, Inc. is offering to exchange its Series B Convertible Preferred Stock, which the Company is valuing at $1.00 per share, for common shares of stock submitted to the Company’s transfer agent by May 18, 2007, which the Company is valuing at $.000625 per share, a premium to the current market price (sted Lifeline Biotechnologies, Inc. is offering to exchange its Series B Convertible Preferred Stock, which the Company is valuing at $1.00 per share, for common shares of stock submitted to the Company’s transfer agent by May 18, 2007, which the Company is valuing at $.001 per share, a premium to the current market price).
